🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

hearinghealthmatters.org/hear-in-privat…

Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System #largeholeclosure #TAVR #EVAR fh-partners.com/news-entries/2…

Nature Communications Medicine has published the positive results of 220 real world patients treated with Neuromod #Lenire #tinnitus treatment device. lenire.com/lenire-real-wo…

Neuromod’s tinnitus treatment system validated by real-world analyses Around 91.5% of patients reported meaningful reductions in tinnitus, outpacing data that granted Neuromod’s system FDA de novo classification in 2023. medicaldevice-network.com/news/neuromod-…

This device tickles the tongue to treat tinnitus wvxu.org/health/2025-04…

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield - businesswire.com/news/home/2025…

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield – Ortho Spine News orthospinenews.com/2025/04/28/mai…

She woke up to cicadas buzzing in her head. Here's how she found relief. usatoday.com/story/life/hea… via @usatoday

Vivasure Perqseal vascular closure system lands CE mark bioworld.com/articles/71916…

Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (#AML) fh-partners.com/news-entries/2…

Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen #AML fh-partners.com/news-entries/2…

Neurent Medical accounts FDA approval of next generation NEUROMARK System for chronic rhinitis. #ENT #rhinitis fh-partners.com/news-entries/2…

Neurent Medical opens new manufacturing facility in Galway to produce next generation Neuromark device for the treatment of chronic #rhinitis #ENT rte.ie/news/business/… via RTÉ

Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe #vascularclosure #TAVR #EVAR fh-partners.com/news-entries/2…

Priothera secures EUR1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program. The funding is to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy fh-partners.com/news-entries/2…

Vivasure Medical submits premarket approval to US FDA for PerQseal Elite closure system - Vascular News vascularnews.com/vivasure-medic…

Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK® #rhinitis #ENT neuromark.com/resource/cigna…

UK clears Bayer's hot flash treatment, marking first approval worldwide - endpoints.news/uk-clears-baye…

Xylocor Therapeutics announces that the first patient has been dosed in the EXACT-2 phase 2b trial of XC001, a novel gene therapy, in patients with coronary artery disease and refractory angina. #angina #CABG #VEGF fh-partners.com/news-entries/2…

Corteria Pharmaceuticals initiates CRAFT-WHF Phase 2 trial in worsening heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists #heartfailure #obesity #cardiovascular  fh-partners.com/news-entries/2…